Jaguar Health, Inc.
200 Pine Street
Suite 400
San Francisco, CA 94104
United States
415 371 8300
https://jaguar.health
版塊: Healthcare
行業: Biotechnology
全職員工: 49
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Ms. Lisa A. Conte | Founder, CEO, President & Director | 610.66k | 無 | 1959 |
| Dr. Pravin R. Chaturvedi Ph.D. | Chief Scientific Officer & Chair of Scientific Advisory Board | 517.91k | 無 | 1963 |
| Mr. Jonathan S. Wolin CPA, J.D., M.B.A. | Chief of Staff, Chief Compliance Officer & General Counsel | 457.61k | 無 | 1962 |
| Dr. Steven R. King Ph.D. | Chief of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Secretary | 406.4k | 無 | 1958 |
| Ms. Carol R. Lizak M.B.A. | Chief Financial Officer | 無 | 無 | 1964 |
| Mr. Peter Hodge | Senior Director of Investor Relations, Business Development & Special Events | 無 | 無 | 無 |
| Dr. Karen J. Brunke Ph.D. | Executive VP of Corporate & Business Development | 無 | 無 | 1953 |
| Mr. David Sesin | Chief Manufacturing Officer | 無 | 無 | 無 |
| Mr. Ian H. Wendt M.B.A. | Chief Commercial Officer | 441.31k | 無 | 1968 |
| Dr. Massimo Radaelli M.B.A., Ph.D. | President of Jaguar International | 無 | 無 | 1958 |
描述
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
公司管治
截至 無 止，Jaguar Health, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
